You are here: Home » Companies » News
Business Standard

Pfizer, P&G stock down by up to 3% on drug ban

Pfizer stopped sale of cough syrups Corex and Phensedyl after govt banned over 300 fixed dose combination drugs

Topics
Pfizer

Press Trust of India  |  Mumbai 

New York City Pfizer World Headquarters   Photo courtesy: Wikimedia commons
New York City Pfizer World Headquarters Photo courtesy: Wikimedia commons

Shares of and Procter and Gamble (P&G) Tuesday fell by up to 3% amid concerns over ban on their popular drug products.

shares went down by 2.88% to Rs 1,710 on BSE as the company has discontinued the manufacture and sale of popular cough syrup Corex with immediate effect.



Shares of had slumped 9% in the previous session also.

P&G's stock fell by 2.21% to Rs 5,992.80 following the company discontinuing manufacture and sale of its popular brand 'Vicks Action 500 Extra' with immediate effect after the government banned fixed dose combination drugs.

On Monday, drug majors Pfizer and Abbott stopped sale of their popular cough syrups Corex and Phensedyl respectively, after the government banned over 300 fixed dose combination (FDCs) drugs.

Pfizer has discontinued the manufacture and sale of Corex cough syrup with immediate effect after the government banned fixed dose combination of Chlopheniramine Maleate+ Codeine Syrup.

"The above prohibition is likely to have an adverse impact on the revenue and profitability of the company. Corex recorded sale of Rs 176 crore for the nine month period ended December 31, 2015," the company had said.

Dear Reader,


Business Standard has always strived hard to provide up-to-date information and commentary on developments that are of interest to you and have wider political and economic implications for the country and the world. Your encouragement and constant feedback on how to improve our offering have only made our resolve and commitment to these ideals stronger. Even during these difficult times arising out of Covid-19, we continue to remain committed to keeping you informed and updated with credible news, authoritative views and incisive commentary on topical issues of relevance.
We, however, have a request.

As we battle the economic impact of the pandemic, we need your support even more, so that we can continue to offer you more quality content. Our subscription model has seen an encouraging response from many of you, who have subscribed to our online content. More subscription to our online content can only help us achieve the goals of offering you even better and more relevant content. We believe in free, fair and credible journalism. Your support through more subscriptions can help us practise the journalism to which we are committed.

Support quality journalism and subscribe to Business Standard.

Digital Editor

First Published: Tue, March 15 2016. 13:15 IST
RECOMMENDED FOR YOU
.